GlobalData on MSN
Shionogi enrols first patients in Esprit trial for Pompe disease
The trial will examine the efficacy, safety, and pharmacodynamics of S-606001 SRT used with ERT in confirmed LOPD adults.
S-606001 has the potential to become the first oral substrate reduction therapy for Pompe diseaseOSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer ...
Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST). This is an ASCO Meeting Abstract from the 2020 Gastrointestinal Cancers Symposium.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results